Khan, Parvez
Siddiqui, Jawed Akhtar
Lakshmanan, Imayavaramban
Ganti, Apar Kishor
Salgia, Ravi
Jain, Maneesh
Batra, Surinder Kumar
Nasser, Mohd Wasim http://orcid.org/0000-0003-2070-4972
Funding for this research was provided by:
National Cancer Institute (R01CA218545, R01CA247471, R01CA247471, R01CA195586, R01CA195586, P01 CA217798, P01 CA217798, P30CA033572, U54CA209978, R01CA247471, R01CA218545, R01CA241752)
U.S. Department of Veterans Affairs (I01 BX004676)
Article History
Received: 29 December 2020
Accepted: 23 February 2021
First Online: 19 March 2021
Declaration
:
: SKB is co-founder of Sanguine Diagnostics and Therapeutics, Inc. AKG is on the advisory board for Blueprint Medicines, Cardinal Health, AstraZeneca, and G1 Therapeutics. He has served as a consultant to AstraZeneca and Genentech, and received research support from Oncoceutics and Takeda Pharmaceuticals. Other authors declare no competing interests.
: Not applicable for this review.
: All authors agree with the content of the manuscript and consent to publication.